Efficacy and Safety of Lorlatinib in ALK+ NSCLC

Efficacy and Safety of Lorlatinib in ALK+ NSCLC

User Photo
AnnualMeeting2017

3 years
1,137 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
H. Jack West, MD of Swedish Cancer Institute discusses an abstract that focused on the efficacy and safety of a third generation ALK inhibitor, lorlatinib, for ALK positive non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 9006: Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
Up Next Autoplay